Improving Prognosis for Kidney Disorders

1. Front Matter

   Pages i-xv

   PDF

2. How to Achieve Maximal Renoprotection in Non-Diabetic Chronic Renal Disease

   • Maarten W. Taal, Barry M. Brenner

   Pages 1-8

3. Anemia of Chronic Kidney Disease and its Management with Recombinant Human Erythropoietin and Darbepoetin Alfa

   • Allen R. Nissenson, Eric M. Tong

   Pages 9-27

4. Cardiovascular Disease in Patients with Chronic Kidney Disease: The Causes and Effects

   • Adeera Levin, Ognjenka Djurdjev, Brendan Barrett, Ellen Burgess, Euan Carlisle, Jean Ethier et al.

   Pages 29-38

5. Metabolic Pathogenesis of Cardio-Renal Disease

   • William F. Keane

   Pages 39-43

6. Oxidative Stress and Inflammation in Hemodialysis Patients

   • Margaret Spittle, Nicholas A. Hoenich, Garry Handelman, Rohini Adhikarla, Peter Homel, Nathan W. Levin

   Pages 45-52

7. Prognostic Value of Enrollment Parathyroid Hormone in Hemodialysis and Peritoneal Dialysis Patients for Survival. A 14 years Follow-up

   • Morrell Michael Avram, Neal Mittman, Maung M. Myint, Paul Fein

   Pages 53-59

8. Prealbumin As an Important Predictor for Survival and Nutritional Status in Hemodialysis and Peritoneal Dialysis Patients

   • Neal Mittman, Morrell Michael Avram, Kyin K. Oo, Jyoti Chattopadhyay

   Pages 61-67

9. How to Attain Optimal Antiproteinuric Dose of Losartan in Non-Diabetic Patients with Nephrotic Range Proteinuria

   • Gozewijn D. Laverman, Robert H. Henning, Paul E. de Jong, Gerjan Navis, Dick de Zeeuw

   Pages 69-73

10. Hypoalbuminemia in the Patient with Renal Disease: Its Causes and Consequences

    • George A. Kaysen

    Pages 75-89

11. Kidney Disease and Mechanisms that Cause Loss of Muscle Mass

    • William E. Mitch, S. Russ Price

    Pages 91-96

12. Role of Plasma Homocysteine and Plasminogen Activator Inhibitor-1 in the Progression of Diabetic Nephropathy

    • Peter Hovind, Lise Tarnow, Peter Rossing, Coen D. A. Stehouwer, Jef J. Emeis, Hans-Henrik Parving

    Pages 97-101

13. Effects of Erythropoietin(EPO)and Aminoguanidine (AG) on Deformability (df) in Diabetic Azotemic and Uremic Patients

    • Clinton D. Brown, Zhong H. Zhao, Lorraine L. Thomas, R. deGroof, Eli A. Friedman

    Pages 103-108

14. Characterization of the PKD 1 Gene Product, Polycystin-1

    • Alessandra Boletta, Feng Qian, Luiz F. Onuchic, Alessandra Bragonzi, Marina Cortese, Pierre J. Courtoy et al.

    Pages 109-118

15. Nutrition and Blood Pressure

    • Joel D. Kopple

    Pages 119-123

16. How to Minimize Bone Disease in Renal Failure

    • Kevin J. Martin, Esther A. González

    Pages 125-131

17. Back Matter

    Pages 133-134

    PDF

More than half a million people worldwide are now sustained by renal replacement therapy, mainly hemodialysis at a cost exceeding USD 30 billion per year. Each case of ESRD that is delayed or prevented saves funds that may be applied to other aspects of health care. Edited by an internationally renowned nephrologist, Prognosis for Kidney Disorders provides a timely summary of exciting work in progress directed toward renoprotection and of ultimate interdiction of ESRD.
Suitable for researchers and clinicians, Dr. Morrell Michael Avram has collected and commented on promising initiatives likely to enter everyday practice in the immediate future. Suitable for renal trainees, experienced kidney doctors, nurses, nutritionists and cardiologists.

• blood pressure
• cardiovascular
• care
• health care
• inflammation
• kidney
• management
• muscle
• nutrition
• stress
• therapy
• vascular disease

• Long Island College Hospital, Brooklyn, USA

  Morrell Michael Avram

Policies and ethics